CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Cadrenal Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.06−0.03 (-2.75%)

Close on Oct 19, 2026

Market cap: $3.09M
P/E (TTM): –
Dividend yield: 1556.60%

Cadrenal Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2008 2008-03-31
Cost of Revenue	–	–	0.22	0.22
Research & Development	4.10	4.21	4.08	0.20
General & Administrative	9.35	6.75	3.55	–
Operating Expenses	13	11	7.63	–
Operating Income	-13	-11	-7.63	–
Interest Expense	–	–	0.00	–
Interest & Investment Income	0.22	0.31	0.25	–
Other Non-Operating Income	0.22	0.31	-0.72	–
Net Income	-13	-11	-8.36	–
Net Income to Common	-13	-11	-8.36	–
EPS (Basic)(per share)	-6.64	-8.73	-9.29	–
EPS (Diluted)(per share)	-6.64	-8.73	-9.29	–
Shares Outstanding (Basic, Weighted)(shares)	1.99	1.22	0.90	–
Shares Outstanding (Diluted, Weighted)(shares)	1.99	1.22	0.90	–
Dividend per Share(per share)	16.50	16.50	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -260.1%

Financial strength

Current ratio: 3.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 159.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.75
Dividend yield: 1556.60%